TrkA antagonists(Nerve growth factor receptor Trk-A antagonists), TrkB inhibitors(Neurotrophic tyrosine kinase receptor type 2 inhibitors), TrkC inhibitors(Neurotrophic tyrosine kinase receptor type 3 inhibitors)

Therapeutic Areas

NeoplasmsNervous System DiseasesEndocrinology and Metabolic Disease+ [4]

Active Indication

NTRK fusion-positive solid tumorsLocally Advanced Malignant Solid NeoplasmBrain metastases+ [9]

Inactive Indication

Metastatic Solid Tumor

Originator Organization

Jiangsu Vcare PharmaTech Co., Ltd.

Active Organization

Jiangsu Vcare PharmaTech Co., Ltd.

Beijing Yiling Bio-engineering Technology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (03 Jun 2026),

NTRK fusion-positive solid tumors

RegulationConditional marketing approval (China), Priority Review (China)

Structure/Sequence

Molecular FormulaC21H22FN7O

InChIKeyURXMBXJZRCIDQB-GOSISDBHSA-N

CAS Registry2396516-98-4

Clinical Trials associated with Eratrectinib

NCT06658353

/ RecruitingPhase 3

Single-arm, Open, Multi-center Phase III Clinical Study to Assess the Safety and Effectiveness of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors

This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.

Start Date17 Mar 2025

Sponsor / Collaborator

Jiangsu Vcare PharmaTech Co., Ltd.

NCT06619951

/ CompletedPhase 1

A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects

This study will adopt a Single-center, Single-arm, Open, Fixed Sequence design to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects.

Start Date18 Sep 2024

Sponsor / Collaborator

Jiangsu Vcare PharmaTech Co., Ltd.

NCT06529445

/ CompletedPhase 1

Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects

This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate Food effect and Relative bioavailability of VC004 Capsules in healthy subjects

Start Date22 Jul 2024

Sponsor / Collaborator

Jiangsu Vcare PharmaTech Co., Ltd.

100 Clinical Results associated with Eratrectinib

100 Translational Medicine associated with Eratrectinib

100 Patents (Medical) associated with Eratrectinib

Literatures (Medical) associated with Eratrectinib

01 Jan 2024·Clinical Drug Investigation

Food Effect on the Pharmacokinetics of VC004, a Tropomyosin Receptor Kinase Inhibitor: A Randomized Crossover Trial in Healthy Chinese Subjects

Article

Author: Wang, Huiping ; Tang, Lu ; Hu, Linlin ; Sun, Qiuyue ; Wu, Yong ; Cai, Mingmin ; Qian, Wei ; Dou, Ting ; Liu, Yongqiang

BACKGROUND AND OBJECTIVE:

VC004 is a novel next-generation tropomyosin receptor kinase (TRK) inhibitor that is approved for the treatment of advanced or metastatic NTRK fusion-positive solid tumors and abrogated the drug resistance of the first-generation TRK inhibitors. The objective of the present study was to evaluate the effect of food on the pharmacokinetics and safety of VC004.

METHODS:

The study was a randomized, open-label, two-period crossover, single-dose, phase I clinical trial. A total of 16 healthy subjects participated the trial. Subjects fasted for 10 h before drug administration in both fasting and fed states. Subjects received VC004 50 mg orally in the fasting state and after a high caloric food in the fed state. Blood samples at the designated time points were collected to determine the plasma concentration of VC004. Safety evaluation in both the fasted and fed periods were assessed via vital sign monitoring and clinical laboratory tests.

RESULTS:

The maximum plasma concentration (C_max) of VC004 in fed group decreased by 32.8%, corresponding with the slower absorption rate (time to C_max (T_max) delayed by almost 3 h) compared with the fasting group. Ratios of geometric means (GMRs) and 90% confidence intervals (90% CIs) of C_max, the area under the curve of plasma concentration-time from zero to the last measurable concentration (AUC_0-t), and AUC from zero to infinity (AUC_0-∞) for VC004 between the two states were 67.18 (58.16-77.60), 103.59 (95.04-112.92) and 103.55 (95.63-112.11), respectively. No serious adverse events (AEs) occurred; only three grade 1 or grade 2 adverse events occurred in the fasted group, who recovered by the end of the study.

CONCLUSIONS:

The intake of high calorie food decreased the absorption rate and increased the T_max of VC004, while the AUC values were similar in both groups. No serious adverse event was reported. In conclusion, food does not alter the pharmacokinetics and safety profile of VC004 in a clinically meaningful manner.

TRIAL REGISTRATION:

ClinicalTrials.gov ID: NCT055528120.

01 Jan 2024·Lung cancer (Amsterdam, Netherlands)

ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report

Article

Author: Lu, Shun ; Gao, Lin ; Ai, Xinghao

INTRODUCTION:

Chromosomal rearrangements involving the neurotrophin kinase (NTRK) genes NTRK1, NTRK2 and NTRK3 with different fusion partners occur in non-small cell lung cancers (NSCLCs) and other solid tumors. Novel NTRK rearrangement-related tumors are still being discovered.

METHODS:

Herin, we describe a male patient with a mass in the left upper lobe that was biopsied by bronchoscopy. This case was diagnosed with stage Ⅳ lung atypical carcinoid (AC) harboring the ETV6::NTRK3 gene fusion.

RESULTS:

He received 1st line treatment with everolimus lasting for 4 months. After chemotherapy failure, he received 3rd treatment with VC004 in a phase 1/2 study and achieved stable disease, but he stopped taking it due to intolerance. He subsequently received repotrectinib treatment and achieved a partial response of more than ten months.

CONCLUSIONS:

To the best of our knowledge, we reported the first case demonstrating anti-tumor activity of repotrectinib in a patient with AC carring an ETV6-NTRK3 gene fusion, indicating that repotrectinib may be an efficient therapeutic option for tumors with NTRK gene rearrangements.

01 Jan 2000·Synapse (New York, N.Y.)Q4 · MEDICINE

Preclinical testing of N-[11c]-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PET

Q4 · MEDICINE

Article

Author: Visser, Thomas Jakob ; Doze, Petra ; Vaalburg, Willem ; Van Waarde, Aren ; Wegman, Theodora

The muscarinic antagonist N-[(11)C]methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate (VC-004) 1 was tested for visualization of muscarinic receptors in the brain. The active (R)-isomer (pKb = 10.92) was labeled by reacting [(11)C]-CH(3)I with the secondary amine precursor (40-60% decay-corrected radiochemical yield, specific activity 13.0-34.3 TBq/mmol, 45 min after end of bombardment). Biodistribution studies were performed in male Wistar rats. Brain uptake of (R)-[(11)C]-VC-004 was high, standard uptake values (SUVs) ranging from 1.6 in cerebellum to 3.3 in frontal cortex. In all brain regions, the nonsubtype selective muscarinic antagonist scopolamine (2.5 mg/kg) blocked (R)-[(11)C]-VC-004 binding to the same extent (84.6 +/- 3.3%) as nonlabeled (R)-VC-004 (2.0 mg/kg, 83.2 +/- 4.6%). In contrast, the fraction of [(11)C]VC-004 binding which was blocked by atropine (2.5 mg/kg) was significantly smaller (54 +/- 17%). The reduction of (R)-[(11)C]-VC-004 binding by low-dose atropine (0.5 mg/kg) was not significantly different from that caused by (R)-(-)-QNB (20 microg/kg). The decrease in specific binding of (R)-[(11)C]VC-004 after (R)-(-)-QNB block correlated well with literature values for the percentages of M(2) receptors in the brain regions studied. (R)-[(11)C]VC-004 was rapidly cleared from plasma (92% with a half-life of 0.27 min) and the fraction of total plasma radioactivity representing parent compound decreased from 99% to 42% at 10 min postinjection. Although (R)-[(11)C]VC-004 can visualize muscarinic receptors in the brain, it does not show selectivity for the M(2)-subtype. A low dose (0.5 mg/kg) of atropine seems to preferentially block M(2)-receptors in vivo, as has been reported for (R)-(-)-QNB.

News (Medical) associated with Eratrectinib

01 Jul 2026

·www.prnewswire.com

NDA for Sumecigrel Capsule, an Antiplatelet Innovative Drug by Vcare PharmaTech, Officially Accepted

June 26, 2026 -- Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially accepted by the NMPA. The drug has now entered the NDA stage. As a global pioneer in novel antiplatelet agents, Sumecigrel is expected to provide a new and improved treatment option to tens of millions of patients with cardiovascular and cerebrovascular diseases. Sumecigrel Capsule is a new-generation oral P2Y12 receptor antagonist, clinically indicated for the treatment and prevention of atherosclerotic thrombotic events, including Acute Coronary Syndrome (ACS), Ischemic Stroke (IS) and Peripheral Arterial Disease (PAD). Designed to address the boxed warning regarding clopidogrel resistance, this drug innovatively optimizes the metabolic pathway of clopidogrel while retaining the molecular discovery pathway of its active metabolite. It aims to strike a better balance between the therapeutic benefits and bleeding risks of antiplatelet medications. A series of completed clinical studies, including Phase I, Phase II, China-US PK/PD bridging study and Phase III trials, have fully validated the clinical efficacy and safety of Sumecigrel Capsule. It boasts multiple advantages including faster onset of action, lower dosage, more stable therapeutic effect, better control of bleeding risks, reduced metabolic burden and broader application scope. The Phase III clinical studies have now been completed. Sumecigrel demonstrated a trend of superior performance over clopidogrel in reducing the risk of MACCE, with more prominent benefits observed in elderly patients, those complicated with anemia, chronic kidney disease and patients undergoing complex PCI with multiple stents, especially high-risk elderly patients aged 75 and above. The drug also shows favorable safety profiles: its major bleeding risk is comparable to that of clopidogrel and better than data from similar studies, with no new unexpected safety signals identified. Against the backdrop of population aging, clinical challenges such as high bleeding risks and complicated combined medication use among elderly cardiovascular patients have become increasingly prominent. Approximately 30% to 40% of patients struggle to achieve a balance between efficacy and safety, leading to huge unmet clinical needs. Sumecigrel effectively addresses the shortcomings of existing drugs and offers a new therapeutic breakthrough for patients with high-risk and complex conditions. Dr. Gong Yanchun, Co-founder, Chairman and CEO of Vcare PharmaTech, stated: "Sumecigrel Capsule is an achievement from the industry-university-research cooperation between our company and China Pharmaceutical University in the early stage. After years of intensive R&D efforts, the NDA has now been accepted, marking a critical milestone. The field of cardiovascular and cerebrovascular disease treatment is in urgent need of high-quality innovative drugs with balanced efficacy and safety to cater to increasingly personalized antiplatelet treatment scenarios. We look forward to the successful launch of Sumecigrel Capsule to benefit patients with cardiovascular and cerebrovascular diseases worldwide." Following the achievement of this key regulatory milestone in China, Vcare PharmaTech will fully advance the subsequent review and approval procedures for marketing. Meanwhile, the company continues to prepare for marketing applications in the United States, the European Union and other countries and regions. In addition, Vcare PharmaTech has entered into an exclusive regional licensing agreement with Everest Medicines for the Asia-Pacific market of Sumecigrel. The company is accelerating the global strategic layout of this product in an all-round manner. Sumecigrel is the world's first new-generation P2Y12 receptor antagonist developed on the premise of retaining the same active metabolite as clopidogrel and optimizing its metabolic pathway to mitigate clopidogrel's heavy reliance on CYP2C19 genetic polymorphism. It is indicated for atherosclerotic thrombotic events including Acute Coronary Syndrome (ACS), Ischemic Stroke (IS) and Peripheral Arterial Disease (PAD). It stands as one of Vcare PharmaTech's representative achievements under the philosophy of "differentiated original design to address unmet clinical needs". The molecular design findings of the drug were published in Journal of Medicinal Chemistry (JMC), a top journal of the American Chemical Society, and highlighted by SciBX under Nature Portfolio, being recognized as "one of the most commercially promising projects in the field of new antiplatelet drugs". Currently, its NDA has been accepted in China, and NDA preparations are underway in the United States, the European Union and other regions. With Best-in-Class potential and broad commercial prospects, Sumecigrel is poised to reshape the antithrombotic drug market, which has seen no innovative drugs targeting the same mechanism launched for more than a decade. Cardiovascular and cerebrovascular diseases refer to a group of functional and organic disorders of the circulatory system, covering diseases related to the heart, blood vessels and neurohumoral systems regulating blood circulation. According to lesion locations and pathological characteristics, they are generally divided into heart diseases, cerebrovascular diseases (such as stroke) and peripheral vascular diseases, forming a multi-level disease spectrum across the whole circulatory system. Atherosclerosis is the major pathological basis of these diseases. Lipid deposition, vascular endothelial injury, inflammatory response and thrombosis may cause vascular stenosis, occlusion or decreased elasticity, further leading to severe conditions such as myocardial ischemia, myocardial infarction, cerebral infarction and cerebral hemorrhage. These diseases are featured by high morbidity, disability, mortality, recurrence rate and numerous complications. Major risk factors include hypertension, hyperlipidemia, hyperglycemia, smoking, excessive drinking, sedentary lifestyle, obesity and advanced age. Mostly developing chronically with acute episodes, they rank as the top chronic diseases threatening the health of middle-aged and elderly people. Cardiovascular and cerebrovascular diseases have become one of the leading causes of death worldwide. The related death toll rose to 17.9 million in 2019, accounting for about 32% of all global deaths in that year, among which around 85% were caused by myocardial infarction (a major type of Acute Coronary Syndrome) and stroke. The latest epidemiological studies show that the death toll from cardiovascular and cerebrovascular diseases further increased to 19.2 million in 2023. Founded in 2010 by professors from China Pharmaceutical University and overseas returnee talents, Jiangsu Vcare PharmaTech Co.,Ltd. is a commercial-stage innovative bio-pharmaceutical enterprise empowered by AI for differentiated original drug design. The company is dedicated to the development of innovative drugs and cutting-edge therapies. Headquartered in the Biomedical Valley of Nanjing Jiangbei New Area, Vcare PharmaTech owns a 21,000 square-meter intelligent R&D headquarters. It has built a full-chain innovation system for independent drug R&D and industrialization, covering AI-driven differentiated project initiation, preclinical candidate discovery, integrated drug development and green manufacturing. The company boasts a strong talent team of more than 900 employees, over 84% of whom are technical staff, including more than 200 talents with master's and doctoral degrees. This high-caliber, professional and innovative core R&D team underpins the company's continuous technological breakthroughs and product iteration. Over sixteen years of dedication to pharmaceutical innovation, Vcare PharmaTech adheres to the core strategy of independent R&D and focuses on addressing unmet clinical needs via differentiated approaches. Centering on overcoming treatment resistance, tackling drug resistance and optimizing target selectivity, the company has established a diversified and high-quality pipeline of innovative drugs covering major chronic disease areas including cardiovascular and cerebrovascular diseases, inflammatory and autoimmune diseases, as well as oncology. Eratrectinib Capsule, a new-generation TRK inhibitor, is clinically used for patients with solid tumors harboring NTRK gene fusions. It delivers a high tumor response rate and strong anti-resistance performance and has been approved for marketing. Sumecigrel Capsule, a new-generation oral P2Y12 receptor antagonist targeting clopidogrel resistance, has had its NDA accepted in China. VC005, a new-generation highly selective JAK1 inhibitor focusing on inflammatory and autoimmune diseases, is in Phase III clinical trials for atopic dermatitis with both oral and topical formulations developed for all patient groups. It is also being explored for ankylosing spondylitis, vitiligo, alopecia areata and other autoimmune diseases, with promising efficacy and safety data. Leveraging years of technological accumulation, Vcare PharmaTech strives to integrate AI capabilities across the entire R&D and production chain, and has established an AI-powered advanced drug R&D system and professional technology platforms. The company has been accredited with multiple honors including Nanjing Key Laboratory for AI-Aided Drug Design and Nanjing Engineering Research Center for Synthetic Biology and Flow Chemistry. Its AI-assisted directed enzyme mutation technology was recognized as an Advanced Cleaner Production Technology of Nanjing. The company has raised over 1.2 billion RMB in total financing in the past five years, winning wide recognition from the capital market. Going forward, adhering to the original aspiration of "The better Care, The better Medicines", Vcare PharmaTech will continue to deepen AI-driven original innovation, make breakthroughs in cutting-edge pharmaceutical technologies and expand its strategic layout at home and abroad. With solid R&D strength and differentiated drug pipelines, the company aims to deliver superior treatment solutions to patients across the globe and grow into a world-class innovative pharmaceutical enterprise. The content above comes from the network. if any infringement, please contact us to modify.

License out/inNDADrug Approval

08 Jun 2026

·allsci.com

China’s NMPA approves Vcare PharmaTech’s eratrectinib for NTRK fusion-positive solid tumors

China’s NMPA has granted marketing approval to eratrectinib (VC004), a next-generation TRK inhibitor developed by Nanjing-based Jiangsu Vcare PharmaTech Co., Ltd., for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions. The tumor-agnostic approval is notable for extending coverage to patients who have progressed on first-generation TRK inhibitors — a population for whom treatment options remain limited — and represents the first domestically developed next-generation TRK inhibitor to reach the Chinese market. Eratrectinib is an oral small-molecule inhibitor that targets the kinase domains of TRKA, TRKB, and TRKC, the proteins encoded by the NTRK1, NTRK2, and NTRK3 genes respectively. Unlike first-generation agents, which feature linear molecular scaffolds susceptible to solvent-front resistance mutations, eratrectinib employs a cyclic molecular structure designed to maintain binding affinity against common acquired resistance mutations while reducing off-target activity. The approval was supported by a Phase II registration study in patients with NTRK fusion-positive solid tumors. In the overall population, eratrectinib demonstrated an objective response rate (ORR) of 68.5% and a disease control rate (DCR) of 85.2%. Among patients with at least six months of follow-up, the ORR reached 89.7% and the DCR was 100%, with a median overall survival of 40.7 months. The two-year progression-free survival rate was 75.7% and the two-year duration of response rate was 85.5%. In patients with baseline brain metastases, the ORR was 87.5%; in those previously treated with TRK tyrosine kinase inhibitors, the ORR was 47.4%. No specific trial identifier was provided in the company’s disclosure. The cyclic scaffold distinguishes eratrectinib from larotrectinib (Vitrakvi), Bayer’s first-generation pan-TRK inhibitor approved by the US FDA in 2018, whose label excludes patients with known acquired resistance mutations. The structural approach is more analogous to that of repotrectinib (Augtyro), Bristol Myers Squibb’s macrocyclic next-generation ROS1/TRK inhibitor that received US FDA accelerated approval in June 2024 for NTRK fusion-positive solid tumors including patients with prior TRK-TKI exposure. The approval for eratrectinib – independently developed by Vcare and unpartnered based on publicly disclosed information – positions Vcare to address the post-first-generation-TKI segment within China, where an estimated 15,000 new NTRK fusion-positive solid tumor cases are diagnosed annually. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug Approval

05 Jun 2026

·www.prnewswire.com

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, more than 229 fusion partner genes have been discovered, giving rise to 358 unique fusion-tumor pairings. Patients harboring such fusions generally have a poor prognosis. For advanced solid tumor patients who do not receive targeted therapy, the median overall survival ranges from 10.2 to 12.7 months, and these patients are also at a higher risk of brain metastasis. Meanwhile, the loss of the extracellular domain in NTRK fusions renders antibody-based therapies ineffective. Currently, treatment primarily relies on small-molecule TRK inhibitors that target the kinase domain.1-3 Continue Reading Vcare PharmaTech Innovative Drug Pipeline In terms of tumor type distribution, NTRK fusions are characterized by rare mutations with broad tumor spectrum distribution. On one hand, the incidence of NTRK fusions reaches up to 90% in rare malignancies such as secretory breast carcinoma and infantile fibrosarcoma, and ranges from 5% to 25% in papillary thyroid carcinoma and Spitzoid melanoma. On the other hand, real-world data from approximately 295,000 solid tumor patients worldwide indicate that NTRK fusion-positive cases account for a larger absolute number of patients among common cancer types. Collectively, NTRK fusion-positive patients with non-small cell lung cancer, breast cancer, soft tissue sarcoma and colorectal cancer make up nearly 50% of all affected cases, representing the key population requiring close clinical attention. In addition, the prevalence of NTRK fusions is higher in East Asian populations, with an overall incidence of approximately 0.4% among Chinese patients. It is estimated that more than 15,000 new cases of NTRK fusion-positive solid tumors are diagnosed in China each year.4-5 Breaking News: Domestic Next-Generation Tumor-Agnostic Targeted Drug Eratrectinib Approved On June 4, the official website of the NMPA announced that Vcare PharmaTech's Class 1 new drug, Eratrectinib, has been approved for marketing in China. It is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions. Efficacy Breakthrough: Eratrectinib Delivers Comprehensive Clinical Benefits Eratrectinib is a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co.,Ltd.. In pivotal registration clinical trials for patients with NTRK fusion-positive solid tumors, this pan-tumor anticancer agent has demonstrated outstanding efficacy and safety. Registration study results showed an ORR of 68.5% and a DCR of 85.2%. Among patients followed up for more than 6 months, the ORR reached 89.7% and the DCR was 100%, with a mOS of 40.7 months.6 In terms of long-term clinical benefits, Eratrectinib also achieved impressive results in PFS and DOR. The 2-year PFS rate stood at 75.7% and the 2-year DOR rate hit 85.5%, fully proving that the drug can deliver sustained disease control and long-term remission for patients. Furthermore, for patients with baseline brain metastases, the ORR was as high as 87.5%. For patients previously treated with TRK-TKIs, the ORR reached 47.4%, reflecting robust therapeutic efficacy across these patient groups. New Hope for Patients with NTRK Fusion Resistance As a next-generation TRK inhibitor independently developed in China, Eratrectinib delivers durable and deep tumor remission, with potent brain penetration and a favorable overall safety profile. Different from the linear structure of first-generation TRK inhibitors, Eratrectinib features a cyclic molecular structure. Structural optimization reduces off-target risks and effectively prevents the emergence of drug-resistant mutations, endowing the agent with the anti-resistance mechanisms characteristic of second-generation TRK inhibitors. About Vcare PharmaTech Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) was co-founded in 2010 by professors from China Pharmaceutical University and overseas returnee experts. As a commercial-stage innovative biopharmaceutical enterprise empowered by AI for differentiated de novo drug design, the Company is dedicated to the development of novel medicines and cutting-edge therapeutics, and has been accredited as a National Key Specialized, Refined, Differential and Innovative "Little Giant" Enterprise. Headquartered in the Biotech and Pharmaceutical Valley of Nanjing Jiangbei New Area, Vcare PharmaTech owns an intelligent R&D headquarters spanning 21,000 square meters. It has built a full-chain innovation system covering independent new drug R&D and industrialization, ranging from AI-powered differentiated target initiation at the early discovery stage, preclinical candidate identification, integrated collaborative pharmaceutical development to green manufacturing. Boasting a robust talent pipeline, the Company employs over 900 staff members, among whom technical professionals account for more than 84%, including over 200 master's and doctoral degree holders. Such a highly educated, specialized and innovation-driven core R&D workforce underpins the Company's sustained technological breakthroughs and product upgrading. Having engaged in pharmaceutical innovation for 16 years, Vcare PharmaTech adheres to the core strategy of indigenous R&D and innovation, targeting unmet clinical needs via differentiated therapeutic approaches. Centered on addressing treatment resistance, overcoming drug resistance and improving target selectivity, the Company has established a high-quality, diversified and tiered innovative drug pipeline covering major chronic illnesses including cardiovascular and cerebrovascular diseases, inflammatory autoimmune disorders and oncology, with its novel pharmaceutical discoveries positioned for global commercialization. The Company's core pipeline candidates feature prominent competitive edges and promising commercial prospects. Eratrectinib (VC004), a next-generation TRK inhibitor and small-molecule targeted anti-tumor agent indicated for solid tumors driven by NTRK gene fusions, delivers tumor-agnostic therapeutic benefits across a broad spectrum of indications and has obtained marketing approval in China. Sumecigrel Capsule, a novel oral P2Y12 receptor antagonist selected four times for China's National Major Science and Technology Projects, precisely inhibits platelet activation and aggregation to block thrombosis for the prevention and treatment of cardiovascular, cerebrovascular and arterial circulatory disorders; its pivotal confirmatory clinical trials are well underway domestically. VC005, a new-generation highly selective JAK1 inhibitor, is being developed via both oral and topical formulations for full-population treatment of atopic dermatitis with all indications in Phase III clinical trials. The asset is also under clinical development for ankylosing spondylitis, vitiligo, alopecia areata and other autoimmune diseases, with robust efficacy and safety data accelerating its clinical progression. Backed by years of technological accumulation, the Company strives to integrate AI capabilities across the entire value chain from early R&D to manufacturing, establishing an AI-enabled premium innovative drug development system and specialized technical platforms. Its R&D platforms have been officially accredited as Nanjing Key Laboratory for AI-Assisted Drug Design and Nanjing Engineering Research Center for Synthetic Biology & Flow Chemistry; its AI-directed site-specific enzyme mutation technology has been recognized as Advanced Cleaner Production Technology by Nanjing authorities. Over the past five years, the Company has secured aggregate financing exceeding RMB 1.2 billion, earning strong recognition from the capital market. Moving forward, abiding by its founding mission of "The better Care, The better Medicines", Vcare PharmaTech will keep advancing AI-driven original innovation and cutting-edge pharmaceutical technologies while expanding its footprint across domestic and overseas markets. Leveraging robust R&D strengths to build a differentiated novel drug portfolio, the company commits to delivering superior therapeutic options for patients worldwide and evolving into a globally influential innovative pharmaceutical enterprise. References: Nguyen MA, et al. Pathology. 2023 Aug;55(5):596-609. Jiang T, et al. Acta Pharm Sin B. 2021 Feb;11(2):355-372. Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. O'Haire S, et al. Sci Rep. 2023 Mar 13;13(1):4116. Qi C, et al. Int J Cancer. 2023 Dec 1;153(11):1916-1927. Vcare Pharma. Phase II Clinical Study Data of Eratrectinib[R] Commercial Cooperation: Strategic Development Director: Dr. Peng, [email protected] BD Director: Liam, [email protected] SOURCE Vcare PharmaTech 21% more press release views with Request a Demo

Drug ApprovalPhase 2Phase 3Clinical Result

100 Deals associated with Eratrectinib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
NTRK fusion-positive solid tumors	China	Jiangsu Vcare PharmaTech Co., Ltd.	03 Jun 2026

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Malignant Solid Neoplasm	Phase 3	China	Jiangsu Vcare PharmaTech Co., Ltd.	17 Mar 2025
Brain metastases	Phase 2	China	Jiangsu Vcare PharmaTech Co., Ltd.	20 Nov 2020
Glioblastoma	Phase 2	China	Jiangsu Vcare PharmaTech Co., Ltd.	20 Nov 2020
Metastatic Solid Tumor	Phase 2	China	Jiangsu Vcare PharmaTech Co., Ltd.	20 Nov 2020
Salivary Gland Neoplasms	Phase 2	China	Jiangsu Vcare PharmaTech Co., Ltd.	20 Nov 2020
Soft Tissue Sarcoma	Phase 2	China	Jiangsu Vcare PharmaTech Co., Ltd.	20 Nov 2020
Thyroid Cancer	Phase 2	China	Jiangsu Vcare PharmaTech Co., Ltd.	20 Nov 2020
Pain	Phase 1	China	Jiangsu Vcare PharmaTech Co., Ltd.	30 Jul 2026
Bone metastases	Phase 1	China	Jiangsu Vcare PharmaTech Co., Ltd.	24 Jul 2026
Cancer Pain	IND Approval	China	Jiangsu Vcare PharmaTech Co., Ltd.	16 Aug 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04614740 (ASCO2024) Manual	Phase 1/2	Locally Advanced Malignant Solid Neoplasm \| Metastatic Solid Tumor NTRK Rearrangement	51	VC004 (all doses)VC004 (all doses)	rvxgrczyie(vwsawrfrjw) = wwudmbtawy wokzrbajgk (uvobmobdvn ) View more	Positive	24 May 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis